Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but the E2211 trial found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone. Study chair Pamela L. Kunz, MD (Yale School of Medicine), presented the findings at the 2022 Annual Meeting of the American Society of Clinical Oncology (Abstract 4004).